Clinical Trials Logo

Abatacept clinical trials

View clinical trials related to Abatacept.

Filter by:
  • None
  • Page 1

NCT ID: NCT04686929 Not yet recruiting - Prevention Clinical Trials

Abatacept s.c. for aGVHD Prevention in Haplo-HCT

Start date: February 1, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Acute graft-versus-host disease (aGVHD) is a potentially fatal complication after allogeneic hematopoietic cell transplantation (HCT), particularly for that with a HLA-mismatched donor. Abatacept has been demonstrated as a potent drug to reduce the risk of aGVHD, but the efficacy of subcutaneous form has yet been investigated. This trial is designed to preliminarily determin the efficacy and saftey of subcutaneous abatacept in the prevention of aGVHD after haplo-identical HCT.